Assessing the Cost-effectiveness of a Hypothetical Disease-Modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease

Malaz Boustani, Erin G. Doty,Louis P. Garrison,Lee J. Smolen,Mark Belger,Timothy M. Klein,Daniel R. Murphy,Russel Burge, J.K. Wall,Joseph A. Johnston

Clinical Therapeutics（2022）

引用 4|浏览2

暂无评分

摘要

Under a set of assumptions for annual treatment costs and the magnitude and duration of treatment efficacy, DMTs used for a limited duration may deliver value consistent with accepted US cost-effectiveness thresholds.

查看译文

关键词

Alzheimer’s disease,cost-effectiveness analysis,disease-modifying therapy,economic evaluation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要